Identification of toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma

Clinical Cancer Research

Volumn 13, Issue 19, 2007, Pages 5703-5709

  Morikawa, Teppei ^a,b   Sugiyama, Akira ^d   Kume, Haruki ^c   Ota, Satoshi ^b   Kashima, Takeshi ^b   Tomita, Kyoichi ^c   Kitamura, Tadaichi ^c   Kodama, Tatsuhiko ^a   Fukayama, Masashi ^b   Aburatani, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^d Perseus Proteomics   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESEARCH; CELL VIABILITY; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, RENAL CELL; DRUG DESIGN; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON INDUCERS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; POLY I-C; TOLL-LIKE RECEPTOR 3;

EID: 35348813788     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0603     Document Type: Article

References (43)

1. Chow WH, Devesa SS, Warren JL, Fraumeni JF, Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628-31.
2. Marumo K, Satomi Y, Miyao N, et al. The prevalence of renal cell carcinoma: a nation-wide survey in Japan in 1997. Int J Urol 2001;8:359-65.
3. Storkel S, Eble JN, Adlakha K, et al.; Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Classification of renal cell carcinoma: Workgroup No. 1. Cancer 1997;80:987-9.
4. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27:612-24.
5. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-17.
6. Iliopoulos O. Molecular biology of renal cell cancer and the identification of therapeutic targets. J Clin Oncol 2006;24:5593-600.
7. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
8. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
9. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
10. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471-84.
11. Schmidt C. Immune system's Toll-like receptors have good opportunity for cancer treatment. J Natl Cancer Inst 2006;98:574-5.
12. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;5:987-95.
13. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 2001;413:732-8.
14. Ruckdeschel K, Pfaffinger G, Haase R, et al. Signaling of apoptosis through TLRs critically involves Toll/IL-1 receptor domain-containing adapter inducing IFN-β, but not MyD88, in bacteria-infected murine macrophages. J Immunol 2004;173:3320-8.
15. Huang B, Zhao J, Li H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005;65:5009-14.
16. Merrell MA, Ilvesaro JM, Lehtonen N, et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 2006;4:437-47.
17. Rayburn ER, Wang W, Zhang Z, Li M, Zhang R, Wang H. Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy. Prostate 2006;66:1653-63.
18. Killeen SD, Wang JH, Andrews EJ, Redmond HP. Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Br J Cancer 2006;95:247-52.
19. Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:992-3.
20. Ishii M, Hashimoto S, Tsutsumi S, et al. Direct comparison of GeneChip and SAGE on the quantitative accuracy in transcript profiling analysis. Genomics 2000;68:136-43.
21. Watanabe A, Hippo Y, Taniguchi H, et al. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res 2003;63:8629-33.
22. Ito H, Funahashi S, Yamauchi N, et al. Identification of ROBO1 as a novel hepatocellular carcinoma antigen and a potential therapeutic and diagnostic target. Clin Cancer Res 2006;12:3257-64.
23. Miyamoto T, Min W, Lillehoj HS. Lymphocyte proliferation response during Eimeria tenella infection assessed by a new, reliable, nonradioactive colorimetric assay. Avian Dis 2002;46:10-6.
24. Matsumoto M, Funami K, Tanabe M, et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003;171:3154-62.
25. Tissari J, Siren J, Meri S, Julkunen I, Matikainen S. IFN-α enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J Immunol 2005;174:4289-94.
26. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001;6:34-55.
27. Qin XQ, Tao N, Dergay A, et al. Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci U S A 1998;95:14411-6.
28. Einhorn S, Grander D. Why do so many cancer patients fail to respond to interferon therapy? J Interferon Cytokine Res 1996;16:275-81.
29. Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J Interferon Cytokine Res 1996;16:759-64.
30. Nakanishi H, Mizutani Y, Kawauchi A, et al. Significant antitumoral activity of cationic multilamellar liposomes containing human IFN-β gene against human renal cell carcinoma. Clin Cancer Res 2003;9:1129-35.
31. Yoshida J, Mizuno M, Wakabayashi T. Interferon-β gene therapy for cancer: basic research to clinical application. Cancer Sci 2004;95:858-65.
32. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006;176:4894-901.
33. Adams M, Navabi H, Croston D, et al. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine 2005;23:2374-8.
34. Meylan E, Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell 2006;22:561-9.
35. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-α or interferon-α plus antivascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004;10:2584-6.
36. Stewart WE II, De Clercq E, Billiau A, Desmyter J, De Somer P. Increased susceptibility of cells treated with interferon to the toxicity of polyriboinosinic-polyribocytidylic acid. Proc Natl Acad Sci U S A 1972;69:1851-4.
37. Linehan WM, Vasselli J, Srinivasan R, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 2004;10:6282-9S.
38. Wornle M, Schmid H, Banas B, et al. Novel role of Toll-like receptor 3 in hepatitis C-associated glomerulonephritis. Am J Pathol 2006;168:370-85.
39. Gongora C, David G, Pintard L, et al. Molecular cloning of a new interferon-induced PML nuclear body-associated protein. J Biol Chem 1997;272:19457-63.
40. Lee TH, Klampfer L, Shows TB, Vilcek J. Transcriptional regulation of TSG6, a tumor necrosis factor- and interleukin-1-inducible primary response gene coding for a secreted hyaluronan-binding protein. J Biol Chem 1993;268:6154-60.
41. Lokich J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol 1997;20:416-8.
42. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and α-interferon as treatment for metastatic renal carcinoma. Br J Urol 1989;63:128-31.
43. Kariko K, Ni H, Capodici J, Lamphier M, Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004;279:12542-50.